The Bioresorbable Drug-Eluting Coronary Stent: The Price Is Right?

Affiliations

Free article

Editorial

Michael A Kutcher. JACC Cardiovasc Interv. 2017.

Free article

. 2017 Apr 24;10(8):783-785.

doi: 10.1016/j.jcin.2017.03.007.

¹ Wake Forest School of Medicine, Winston-Salem, North Carolina. Electronic address: mkutcher@wakehealth.edu.

No abstract available

Keywords: absorb stent(s); bioresorbable stent(s); health care economics.

Comment on

Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
Baron SJ, Lei Y, Chinnakondepalli K, Vilain K, Magnuson EA, Kereiakes DJ, Ellis SG, Stone GW, Cohen DJ; ABSORB III Investigators. Baron SJ, et al. JACC Cardiovasc Interv. 2017 Apr 24;10(8):774-782. doi: 10.1016/j.jcin.2017.01.022. JACC Cardiovasc Interv. 2017. PMID: 28427593 Clinical Trial.